Affimed (AFMD) has released an update.
Affimed N.V., a clinical-stage oncology firm, has announced the appointment of Shawn M. Leland as its new CEO. Leland brings over 15 years of industry experience, having raised substantial capital for biotech companies and led crucial partnerships and licensing deals. His previous role as the interim CEO of ForeBio and his achievements, including a $75M Series D financing round, position him to propel Affimed’s growth and strategic development.
For further insights into AFMD stock, check out TipRanks’ Stock Analysis page.
